Sofosbuvir
Sofosbuvir/velpatasvir with ribavirin improves liver, renal function in chronic HCV
BOSTON — A regimen of sofosbuvir/velpatasvir with ribavirin was effective among patients with refractory chronic hepatitis C virus with liver cirrhosis and chronic kidney disease, according to data presented at The Liver Meeting.
National virtual HCV program expands access to care for children, adolescents in the UK
BOSTON — A virtual treatment program that coordinates care with local providers improved therapy for children and adolescents with hepatitis C virus in the United Kingdom, according to a presentation at The Liver Meeting.
Point-of-diagnosis HCV treatment model yields 95% SVR at 12 weeks among marginalized group
A test-and-treat model for hepatitis C virus infection among injection drug users and people experiencing homelessness resulted in high levels of treatment initiation, completion and cure, and may expand care access to marginalized groups.
VIDEO: Access to generic DAA treatment critical for HCV elimination
BOSTON — Treatment of hepatitis C virus infection in low- and middle-income countries is key to global elimination efforts, according to an abstract presented at The Liver Meeting.
Sofosbuvir-based regimens demonstrate durable SVR in children with HCV
BOSTON — Treatment with sofosbuvir-based direct-acting antivirals demonstrated durable sustained virologic response up to 5 years among pediatric patients with hepatitis C virus, according to findings presented at The Liver Meeting.
Sofosbuvir/velpatasvir with tenofovir alafenamide efficacious for HCV, HBV co-infection
BOSTON — After 12 weeks of treatment with sofosbuvir/velpatasvir in combination with tenofovir alafenamide, patients with hepatitis C virus and hepatitis B virus co-infection demonstrated high rates of sustained virologic response.
Transplantation within 7 days of listing boosts survival in acute-on-chronic liver failure
LONDON — Early liver transplantation within 7 days of listing was linked to improved 90-day and 1-year survival among patients with grade 3 acute-on-chronic liver failure, according to data presented at the International Liver Congress.
WHO: HCV elimination by 2030 demands ‘scale-up, simplification’ of care pathways
LONDON —WHO presented updated guidance on hepatitis C, calling for drastic simplification of care pathways to alleviate access gaps in HCV testing and treatment, during a joint WHO-EASL-CDC symposium at the International Liver Congress.
Minimal monitoring induces sustained virological response in HCV
Among patients treated with sofosbuvir and velpatasvir for hepatitis C virus, the minimal monitoring approach achieved sustained virological response similar to standard monitoring, according to research.
VIDEO: HCV retreatment regimen benefited patients who failed therapy
Healio spoke with Nancy S. Reau, MD, FAASLD, AGAF, about a study evaluating a hepatitis C retreatment regimen in patients who failed therapy with Vosevi.